Subcutaneous Immunoglobulin Market Is Anticipated To Reach US$8,831.3 Mn By 2024

Press Release

Global Subcutaneous Immunoglobulin Market: Snapshot

Immunoglobulins are unique biologic medicines that can be either infused or injected to treat rare, life-threatening, chronic, and genetic diseases. These diseases include bleeding disorders, immune deficiencies, pulmonary disorders, neurological disorders, and infectious diseases such as tetanus, hepatitis, and rabies. Factors such as growing use of immunoglobulins in primary immunodeficiency disorders and widespread opportunities for immunoglobulins in the treatment of secondary immunodeficiency diseases such as AIDS are responsible for growth of the subcutaneous immunoglobulin market. Better access to medicines in emerging markets due to increasing government support, increase in new indications in the geriatric population, and the development of new plasma-derived formulations are likely to drive the subcutaneous immunoglobulin market.

Transparency Market Research estimates that the subcutaneous immunoglobulin market will expand at a CAGR of 14.0% over the forecast period between 2016 and 2024. Escalating at this pace, the market, which had a valuation of US$2,762.2 Mn in 2015 in terms of revenue, is projected to rise to US$8,831.3 Mn by 2024.

PIDDs to Dominate Demand from Subcutaneous Immunoglobulin Market

The subcutaneous immunoglobulin market has been assessed in terms of application and end user. In terms of application, the subcutaneous immunoglobulin market is categorized into primary immunodeficiency diseases, secondary immunodeficiency diseases, and others. In terms of revenue, primary immunodeficiency diseases held the largest share in 2015 and are projected to dominate the market during the forecast period. Primary immunodeficiency diseases held a share of 68.9% in 2015. The dominance of the segment can be attributed to the rising prevalence of primary immunodeficiency diseases (PIDDs), growing indication of subcutaneous immunoglobulin, and rising research and development activities in the field of plasma derived therapeutics.

Request Sample @

In terms of end users, the subcutaneous immunoglobulin market is segmented into hospitals, home care, and clinics. The home care segment is expected to gather significant revenue during the forecast period from 2016 to 2024. Subcutaneous infusion of immunoglobulin is rapidly gaining preference over intravenous route of administration. SCIG can be self-administered once a patient has been trained by a health care professional. Immunoglobulin administration through subcutaneous route has demonstrated to be equally therapeutically effective in preventing infections and has considerably low risk. Home care accounted for US$1.7 bn in the global subcutaneous immunoglobulin market in 2015 and is likely to remain a leading contributor over the 2016-2024 forecast period.

North America Likely to Dominate due to Widespread Support for Healthcare Technology Upgrades

Geographically, subcutaneous immunoglobulin market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America dominated the subcutaneous immunoglobulin market in terms of revenue in 2015 and is projected to retain its dominant position during the forecast period from 2016 to 2024. Usage of immunoglobulins is high in North America primarily due to steady approval for new indications and research undertakings, and increasing geriatric population. According to the Immune Deficiency Foundation, currently around 55,000 people in the U.S. with antibody deficiency receive PIDD treatment in the form of intravenous immunoglobulin. Expected launch of immunoglobulins that are presently in clinical trials in the U.S. during the forecast period is likely to boost market growth.

Request Customization @

The North America market for subcutaneous immunoglobulin was valued at US$1,059 mn in 2014 and is likely to rise to US$3,525 mn by the end of 2024.

Key companies profiled in the report include Grifols S.A., CSL Behring LLC, Shire Plc., Biotest AG, Kedrion S.p.A., Octapharma AG, Baxalta Incorporated, and Talecris Biotherapeutics, Inc.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge. 

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

Contact Us

Transparency Market Research

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: [email protected]